stockportfolio.pro
Stocks / MRNA vs MTD
MRNA vs MTD
Moderna, Inc. and Mettler-Toledo International Inc. side by side — fundamentals from SEC filings, refreshed nightly. Sector: Healthcare.
MRNA is the larger company ($24.5B vs $22.8B). On the fundamentals, MRNA grows revenue faster (19.3% vs 5.5%); MTD earns a higher net margin (21.6% vs -145.2%); MRNA has the stronger return on equity (-32.6% vs -3677.4%). Full numbers below — the stronger figure on each row is in green.
| Moderna, Inc. (MRNA) | Mettler-Toledo International Inc. (MTD) | |
|---|---|---|
| Market cap | $24.5B | $22.8B |
| Revenue (latest FY) | $1.94B | $4.03B |
| Net income (latest FY) | $-2.82B | $869.19M |
| Revenue growth (5y CAGR) | 19.3% | 5.5% |
| Net margin | -145.2% | 21.6% |
| Return on equity | -32.6% | -3677.4% |
| P/E ratio | — | 26.5 |
| Dividend yield | — | — |
| Profitable years (of last 10) | 2 | 10 |
| Positive free cash flow | No | Yes |
Compare with another company:
See the full MRNA vs MTD breakdown
Both companies across 19 years of income statement, balance sheet and cash flow — with ratios, health checks and Ask, the SEC-grounded research assistant. Free, no account needed.
Open MRNA's full financials → Open MTD's full financials →More comparisons
Frequently asked questions
Which is bigger, MRNA or MTD?
Moderna, Inc. is larger by market capitalization — $24.5B versus $22.8B.
Which grows faster, MRNA or MTD?
Over the last five fiscal years, Moderna, Inc. grew revenue faster — 19.3%/yr versus 5.5%/yr, computed from SEC-filed statements.
Where does this data come from?
All figures are computed from official SEC filings (10-K), refreshed nightly. This is a data comparison, not investment advice.